| | IXCHIQ For chikungunya virus | — | 08/25/2025 9:36 AM | Provided Update | | |
| | IGC-AD1 For Agitation in Alzheimer's disease. | Phase 2 | 08/25/2025 9:34 AM | Provided Update | | |
AMGN | Amgen Inc
| Repatha (Evolocumab) HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events | — | 08/25/2025 9:33 AM | FDA Approval | | |
PDSB | PDS Biotechnology Corp
| VERSATILE-002 Treatment of recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer. | Phase 2 | 08/25/2025 8:37 AM | Survival data | | |
BFFTFBFRA | Biofrontera AG
| Ameluz For treatment of actinic keratosis | Phase 2b | 08/25/2025 8:25 AM | evaluation | | |
CPRX | Catalyst Pharmaceuticals Inc
| FIRDAPSE® For the treatment of LEMS | — | 08/25/2025 8:16 AM | Provided Update | | |
AMRN | Amarin Corp PLC
| VASCEPA/VAZKEPA (icosapent ethyl) Prior Peripheral Artery Disease (PAD) | — | 08/25/2025 8:14 AM | Presentation | | |
NTRA | Natera Inc
| Signatera MRD Test for cancer therapies | — | 08/25/2025 8:13 AM | New Data | | |
| | COYA 302 For the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Investigational New Drug (IND) | 08/25/2025 8:12 AM | FDA Accepted | | |
EOLS | Evolus Inc
| Evolysse™ Evolus dermal filler, | — | 08/25/2025 8:11 AM | Top-line results | | |
ARTL | Artelo Biosciences Inc
| ART26.12 For the prevention of chemotherapy-induced peripheral neuropathy, a debilitating and often treatment-altering side effect of cancer therapy. | — | 08/25/2025 7:35 AM | Results | | |
BBIO | BridgeBio Pharma Inc
| Acoramidis (ATTRibute-CM) Symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) | — | 08/25/2025 7:35 AM | Oral presentation | | |
CYTK | Cytokinetics Inc
| Aficamten Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) | — | 08/25/2025 7:32 AM | Presentation | | |
ALKS | Alkermes PLC
| ALKS 2680 For the treatment of narcolepsy | — | 08/25/2025 7:18 AM | presented results | | |
SION | Sionna Therapeutics Inc
| SION-451 cystic fibrosis transmembrane conductance regulator (CFTR) protein | Phase 1 | 08/25/2025 7:17 AM | Dose Update | | |
CSTL | Castle Biosciences Inc
| DecisionDx-SCC High-risk cutaneous squamous cell carcinoma (SCC) | — | 08/25/2025 7:16 AM | Publication | | |
PTGX | Protagonist Therapeutics Inc
| Rusfertide (PTG-300) Polycythemia vera (PV) | Breakthrough Therapy Designation | 08/25/2025 7:15 AM | Designation Grant | | |
SBBPXERS | Strongbridge Biopharma PLC Xeris Pharmaceuticals Inc
| RECORLEV (levoketoconazole) Endogenous Cushing's syndrome | — | 08/25/2025 7:14 AM | Provided Update | | |
LIANBMYBMYMP | LianBio Bristol-Myers Squibb Company
| CAMZYOS® (mavacamten) For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy | — | 08/25/2025 7:13 AM | Presentation | | |
MRK | Merck & Co Inc
| VERQUVO (vericiguat) Chronic Heart Failure and Reduced Ejection Fraction | — | 08/25/2025 7:11 AM | Clinical Trial | | |
TBPH | Theravance Biopharma Inc
| Ampreloxetine Symptomatic neurogenic orthostatic hypotension | Phase 3 | 08/25/2025 7:05 AM | Enrollment Completion | | |
BIIB | Biogen Inc
| Lecanemab (BAN2401) Anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD) | — | 08/25/2025 3:05 AM | Provided Update | | |
ARGNFARGX | argenx SE
| VYVGART (efgartigimod alfa) For Adults with Primary Immune Thrombocytopenia | — | 08/25/2025 1:45 AM | Top-line data | | |
MRNA | Moderna Inc
| SPIKEVAX (COVID-19 Vaccine, mRNA) COVID-19 in individuals 18 years of age and older | Health Canada | 08/22/2025 9:25 AM | Authorization | | |
CTXR | Citius Pharmaceuticals Inc
| LYMPHIR For the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma | — | 08/22/2025 8:50 AM | Provided Update | | |
STTK | Shattuck Labs Inc
| SL-325 In inflammatory bowel disease | Investigational New Drug (IND) | 08/21/2025 2:22 AM | Provided Update | | |
JAGX | Jaguar Health Inc
| Canalevia-CA1 For the treatment of chemotherapy-induced diarrhea (CID) in dogs. | — | 08/21/2025 9:03 AM | Provided Update | | |
CRNX | Crinetics Pharmaceuticals Inc
| Atumelnant In Congenital Adrenal Hyperplasia (CAH) | Orphan Drug Designation | 08/21/2025 8:45 AM | Designation Grant | | |
ABBV | AbbVie Inc
| RINVOQ (upadacitinib) Moderate to Severe Atopic Dermatitis | — | 08/21/2025 8:43 AM | Top-line results | | |
SEPN | Septerna Inc
| SEP-631 For Mast Cell Diseases | Phase 1 | 08/21/2025 8:41 AM | Dosing Update | | |
| | TYRA-300 For the Treatment of Achondroplasia | Phase 2 | 08/21/2025 8:39 AM | Dose Update | | |
DVAX | Dynavax Technologies Corp
| Z-1018 Shingles Vaccine Profile | Phase 1/2 | 08/21/2025 8:37 AM | Top-line results | | |
PTIX | Protagenic Therapeutics Inc
| PT00114 Depression, PTSD, Anxiety and Addiction | — | 08/21/2025 8:22 AM | Dosing Update | | |
EVOK | Evoke Pharma Inc
| GIMOTI (metoclopramide) nasal spray Acute and recurrent diabetic gastroparesis | — | 08/21/2025 7:33 AM | Provided Update | | |
PRTCPTCHF | PureTech Health PLC
| LYT-100 Idiopathic Pulmonary Fibrosis | — | 08/21/2025 7:31 AM | Provided Update | | |
REGN | Regeneron Pharmaceuticals Inc
| EYLEA (aflibercept) Wet age-related macular degeneration (wet AMD) | European Commission Approval | 08/21/2025 4:49 AM | Approved | | |
RYTM | Rhythm Pharmaceuticals Inc
| Setmelanotide (HO) Hypothalamic Obesity | supplemental New Drug Application (sNDA) | 08/20/2025 1:58 AM | FDA Accepted | | |
SVRA | Savara Inc
| Molgramostim (IMPALA-2) Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Phase 2 | 08/20/2025 1:54 AM | Results | | |
| | TH104 For Chronic Pruritis in Primary Biliary Cholangitis (PBC) | — | 08/20/2025 8:47 AM | Positive Results | | |
EOLS | Evolus Inc
| Evolysse™ Evolus dermal filler, | — | 08/20/2025 8:46 AM | Application Submitted | | |
BMYBMYMP | Bristol-Myers Squibb Company
| Opdivo (nivolumab) Resected esophageal or gastroesophageal junction (GEJ) cancer in the adjuvant setting | — | 08/20/2025 8:43 AM | FDA Approval | | |
RCKT | Rocket Pharmaceuticals Inc
| RP-A501 Danon Disease | — | 08/20/2025 7:11 AM | Lifted Clinical Hold | | |
NVCR | NovoCure Ltd
| Tumor Treating Fields - PANOVA-3 Locally advanced pancreatic cancer | — | 08/20/2025 7:09 AM | Application Submitted | | |
PFE | Pfizer Inc
| PAXLOVID Covid-19 | — | 08/20/2025 7:08 AM | Provided Update | | |
CTSO | CytoSorbents Corp
| DrugSorb-ATR Antithrombotic Removal System | — | 08/20/2025 7:07 AM | Regulatory Update | | |
CLDX | Celldex Therapeutics Inc
| Barzolvolimab For Prurigo Nodularis | Phase 2 | 08/19/2025 2:19 AM | Top-line results | | |
MDGL | Madrigal Pharmaceuticals Inc
| Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. | European Commission Conditional Marketing Authorization | 08/19/2025 2:19 AM | Marketing authorization | | |
HCM | HUTCHMED (China) Limited
| SANOVO for Certain Lung Cancer Patients | Phase 3 | 08/19/2025 2:11 AM | Enrollment Completion | | |
JAGX | Jaguar Health Inc
| Crofelemer Microvillus inclusion disease (MVID) - Rare congenital diarrheal disorder | — | 08/19/2025 9:04 AM | Provided Update | | |
| | tafenoquine For treatment of babesiosis | Phase 2 | 08/19/2025 8:54 AM | Provided Update | | |
MREO | Mereo BioPharma Group PLC
| Vantictumab for Autosomal Dominant Osteopetrosis Type 2 | — | 08/19/2025 8:36 AM | Provided Update | | |
| | ANKTIVA For Bacillus Calmette-Guérin | Phase 3 | 08/19/2025 8:35 AM | Provided Update | | |
DCTH | Delcath Systems Inc
| HEPZATO KIT For the treatment of metastatic uveal melanoma (mUM). | Phase 2 | 08/19/2025 8:33 AM | Dose Update | | |
MIRA | MIRA PHARMACEUTICALS, INC.
| Ketamir-2 To treat depression and treatment-resistant depression (TRD). | Phase 1 | 08/19/2025 8:32 AM | Dose Update | | |
PHGEPHGE.U | BiomX Inc
| BX004 Cystic Fibrosis | Phase 2b | 08/19/2025 8:19 AM | Clinical Hold | | |
SILO | SILO Pharma Inc
| SPC-15 Treatment for PTSD | — | 08/19/2025 8:17 AM | Results | | |
ALRN | Aileron Therapeutics Inc
| LTI-03 In Idiopathic Pulmonary Fibrosis | Phase 2 | 08/19/2025 8:03 AM | Clinical Trial | | |
ALXO | ALX Oncology Holdings Inc
| ALX2004 For the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors | — | 08/19/2025 8:02 AM | Dose Update | | |
ALT | Altimmune Inc
| pemvidutide for the treatment of obesity and MASH | Fast Track Designation | 08/19/2025 7:38 AM | Decision Deferred | | |
VKTX | Viking Therapeutics Inc
| VK2735 Metabolic disorders | Phase 2 | 08/19/2025 7:24 AM | Top-line results | | |
ALDX | Aldeyra Therapeutics Inc
| ADX-2191 Primary vitreoretinal lymphoma (PVRL) | Fast Track Designation | 08/19/2025 7:23 AM | Designation Grant | | |
BTAI | BioXcel Therapeutics Inc
| BXCL501 (SERENITY) Schizophrenia and bipolar disorders | Phase 3 | 08/19/2025 7:15 AM | Provided Update | | |
RGNX | Regenxbio Inc
| RGX-121 MPS II (Hunter Syndrome) | Biologics License Applications (BLA) | 08/18/2025 2:38 AM | Provided Update | | |
| | VYD2311 Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ | — | 08/18/2025 2:37 AM | Data | | |
IOVA | Iovance Biotherapeutics Inc
| Lifileucel For the Treatment of Advanced Melanoma | — | 08/18/2025 2:31 AM | Notice of Compliance | | |
MMSI | Merit Medical Systems Inc
| WRAPSODY Cell-Impermeable Endoprosthesis (CIE). | — | 08/18/2025 2:24 AM | Enrollment Update | | |
CAPR | Capricor Therapeutics Inc
| StealthX exosome-based vaccine. | Phase 1 | 08/18/2025 9:02 AM | Dose Update | | |
| | eRapa In Familial Adenomatous Polyposis | — | 08/18/2025 8:34 AM | Enrollment Update | | |
NMTC | NeuroOne Medical Technologies Corp
| OneRF Ablation System for creation of radiofrequency ("RF") lesions in nervous tissue for functional neurosurgical procedures. | — | 08/18/2025 8:31 AM | FDA Clearance | | |
RDY | Dr Reddy's Laboratories Ltd
| Carac For the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp. | — | 08/18/2025 8:17 AM | Launch | | |
SVRA | Savara Inc
| Molgramostim (IMPALA-2) Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | — | 08/18/2025 8:13 AM | FDA Accepted | | |
IRD | Opus Genetics
| OPGx-BEST1 For the treatment of bestrophin-1 (BEST1)-related IRD. | Investigational New Drug (IND) | 08/18/2025 8:07 AM | FDA Accepted | | |
RARE | Ultragenyx Pharmaceutical Inc
| DTX401 AAV For the Treatment of Glycogen Storage Disease Type Ia (GSDIa) | Biologics License Applications (BLA) | 08/18/2025 8:02 AM | rolling submission | | |
ENLV | Enlivex Therapeutics Ltd
| Allocetra Sepsis | — | 08/18/2025 7:58 AM | Top-line results | | |
SNGX | Soligenix Inc
| SGX945 In the Treatment of Aphthous Ulcers in Behçet's Disease | Orphan Drug Designation | 08/18/2025 7:33 AM | Designation Grant | | |
PSTV | Plus Therapeutics Inc
| REYOBIQ™ For Patients with Leptomeningeal Metastases | Phase 1 | 08/18/2025 7:32 AM | Positive Data | | |
| | UNI-494 In the progression of acute kidney injury and chronic kidney disease. | — | 08/18/2025 7:14 AM | Provided Update | | |
VNDA | Vanda Pharmaceuticals Inc
| HETLIOZ For treat jet lag disorder | — | 08/18/2025 7:09 AM | Regulatory Update | | |
LH | Labcorp
| Lumipulse® Blood Test for Alzheimer's Disease | — | 08/18/2025 7:08 AM | Provided Update | | |
BTAI | BioXcel Therapeutics Inc
| BXCL501 (SERENITY) Schizophrenia and bipolar disorders | supplemental New Drug Application (sNDA) | 08/18/2025 7:05 AM | Positive Opinion | | |
MRK | Merck & Co Inc
| I-DXd In patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). | Breakthrough Therapy Designation | 08/18/2025 7:03 AM | Designation Grant | | |
PFE | Pfizer Inc
| PAXLOVID Covid-19 | Phase 2 | 08/18/2025 7:02 AM | evaluation | | |
BMYBMYMP | Bristol-Myers Squibb Company
| iza-bren For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer | Breakthrough Therapy Designation | 08/18/2025 6:25 AM | Designation Grant | | |
NTRA | Natera Inc
| IMvigor011 In Muscle-Invasive Bladder Cancer | Phase 3 | 08/18/2025 6:22 AM | Positive Results | | |
AAPG | Ascentage Pharma
| lisaftoclax In Venetoclax-Refractory Patients | — | 08/17/2025 2:27 AM | FDA Clearance | | |
NONOFNVOVERU | Novo Nordisk A/S Veru Inc
| Wegovy For cardiovascular risk reduction in adults with known heart disease and overweight or obesity | — | 08/15/2025 2:24 AM | FDA approved | | |
TNXP | Tonix Pharmaceuticals Holding Corp
| Tonmya For the management of fibromyalgia. | — | 08/15/2025 4:22 PM | FDA approved | | |
GBT | Global Blood Therapeutics Inc
| Inclacumab + GBT601 Sickle Cell Disease | Phase 3 | 08/15/2025 4:19 PM | Results | | |
BIOA | BioAge Labs Inc
| BGE-102 For the treatment of obesity. | Phase 1 | 08/15/2025 9:01 AM | Dose Update | | |
PGEN | Precigen Inc
| PAPZIMEOS For Treatment Of Adults With Recurrent Respiratory Papillomatosis | — | 08/15/2025 7:40 AM | FDA approved | | |
AKRO | Akero Therapeutics Inc
| Efruxifermin (HARMONY) Non-alcoholic steatohepatitis (NASH) | — | 08/14/2025 3:35 AM | Publication | | |
| | VYD2311 Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ | — | 08/14/2025 4:50 PM | Provided Update | | |
TIZAFTLSA | Tiziana Life Sciences PLC
| Foralumab Crohn's disease with decreases in the classic side effects of cytokine release syndrome | Phase 2a | 08/14/2025 8:39 AM | Enrollment Update | | |
ENLV | Enlivex Therapeutics Ltd
| Allocetra Sepsis | Phase 2a | 08/14/2025 8:08 AM | Presentation | | |
SRRK | Scholar Rock Holding Corp
| Apitegromab Type 2 and Type 3 Spinal Muscular Atrophy (SMA) | — | 08/14/2025 8:07 AM | Published Results | | |
BEAM | Beam Therapeutics Inc
| BEAM-101 Sickle cell diseas | Regenerative Medicine Advanced Therapy (RMAT) Designation | 08/14/2025 7:27 AM | Designation Grant | | |
ATHA | Athira Pharma Inc
| ATH-1105 For Amyotrophic Lateral Sclerosis | Phase 1 | 08/14/2025 7:26 AM | presented results | | |
SMMT | Summit Therapeutics Inc
| Ivonescimab For Lung cancer | Phase 3 | 08/14/2025 7:23 AM | Data | | |
| | VS-7375 In Advanced Solid Tumors | Phase 1/2 | 08/13/2025 6:09 PM | Efficacy and Safety Data | | |
NUVL | Nuvalent, Inc.
| zidesamtinib ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib | Phase 1/2 | 08/13/2025 5:10 PM | Data | | |
PRTCPTCHF | PureTech Health PLC
| VE202 Inflammatory Bowel Disease | Phase 2 | 08/13/2025 5:08 PM | Endpoint Missed | | |
CELZ | Creative Medical Technology Holdings Inc
| CELZ-201-DDT For Chronic Back Pain | Fast Track Designation | 08/13/2025 9:07 AM | Designation Grant | | |
MDWD | MediWound Ltd
| EscharEx Chronic Wounds | — | 08/13/2025 8:48 AM | Publication | | |
MYNZ | Mainz Biomed N.V.
| ColoAlert In the early detection of cancer | — | 08/13/2025 8:45 AM | Provided Update | | |
| | QUILT-106 Patients Treated With CD19 CAR-NK Therapy | Phase 1 | 08/13/2025 8:41 AM | Findings Update | | |
| | Telitacicept For the treatment of autoimmune diseases. | Phase 3 | 08/13/2025 8:39 AM | Primary Endpoint | | |
ALGS | Aligos Therapeutics Inc
| ALG-000184 Hepatitis B | Phase 2b | 08/13/2025 8:35 AM | Dose Update | | |
INVA | Innoviva Inc
| XACDURO® XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is a combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor | — | 08/13/2025 8:23 AM | Provided Update | | |
CTMX | CytomX Therapeutics Inc
| CX-2051 A Probody® Antibody Drug Conjugate (ADC) | Phase 1 | 08/13/2025 8:18 AM | Provided Update | | |
| | TH104 For Chronic Pruritis in Primary Biliary Cholangitis (PBC) | — | 08/13/2025 8:16 AM | Provided Update | | |
APVO | Aptevo Therapeutics Inc
| APVO442 Solid Tumors | — | 08/13/2025 8:14 AM | Provided Update | | |
MRK | Merck & Co Inc
| KEYNOTE-689 In Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma | Health Canada Approval | 08/13/2025 7:20 AM | Approved | | |
OCGN | Ocugen Inc
| OCU410ST For Stargardt Disease | European Medicines Agency (EMA) | 08/13/2025 7:17 AM | review | | |
GLSI | Greenwich LifeSciences Inc
| GLSI-100 Breast cancer recurrences | — | 08/13/2025 7:16 AM | Provided Update | | |
CGTX | Cognition Therapeutics, Inc.
| CT1812 Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex. | Phase 2 | 08/12/2025 4:38 PM | Meeting minutes | | |
INSM | Insmed Inc
| Brensocatib In Patients with Bronchiectasis | — | 08/12/2025 4:35 PM | FDA approved | | |
MIRA | MIRA PHARMACEUTICALS, INC.
| Ketamir-2 To treat depression and treatment-resistant depression (TRD). | — | 08/12/2025 9:26 AM | Provided Update | | |
| | SENTI-202 Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia | — | 08/12/2025 9:16 AM | Provided Update | | |
| | IGC-M3 Alzheimer's disease | — | 08/12/2025 9:05 AM | Promising data | | |
| | AMPLIFY-201 In gastrointestinal tumors | Phase 1 | 08/12/2025 8:09 AM | Publication | | |
AARD | Aardvark Therapeutic Inc
| ARD-201 For the treatment of metabolic obesity and obesity-related conditions. | — | 08/12/2025 8:06 AM | Positive Data | | |
| | AN2-502998 For Chagas Disease | — | 08/12/2025 7:04 AM | Dose Update | | |
OCUL | Ocular Therapeutix Inc
| AXPAXLI In Diabetic Retinopathy | — | 08/12/2025 6:37 AM | Provided Update | | |
MRK | Merck & Co Inc
| EV-303 For Certain Patients with Muscle-Invasive Bladder Cancer | Phase 3 | 08/11/2025 4:57 PM | Top-line results | | |
NVCT | Nuvectis Pharma, Inc.
| NXP900 Novel inhibitor of the SRC family of kinases | Phase 1b | 08/11/2025 4:44 PM | Provided Update | | |
TIZAFTLSA | Tiziana Life Sciences PLC
| Foralumab Crohn's disease with decreases in the classic side effects of cytokine release syndrome | Investigational New Drug (IND) | 08/11/2025 9:02 AM | FDA approved | | |
INO | Inovio Pharmaceuticals Inc
| INO-3107 For the Treatment of Recurrent Respiratory Papillomatosis | — | 08/11/2025 8:25 AM | Peer-reviewed data | | |
IOBT | IO Biotech
| Cylembio For the Treatment of First-line Advanced Melanoma | Phase 3 | 08/11/2025 8:08 AM | Top-line results | | |
| | Pressure-Enabled Drug DeliveryTM (PEDD) For the treatment of patients with symptomatic thyroid disease. | — | 08/11/2025 8:06 AM | Publication | | |
NRXP | NRx Pharmaceuticals
| NRX-100 To treat acute depression and suicidality | Fast Track Designation | 08/11/2025 8:04 AM | Designation Grant | | |
QNTM | Quantum BioPharma Ltd
| Lucid-MS For people to gain back mobility lost with multiple sclerosis (MS). | — | 08/11/2025 7:48 AM | Provided Update | | |
IMAB | I-MAB
| Givastomig In patients with advanced cancers | Phase 1b | 08/11/2025 7:12 AM | Enrollment Update | | |
GTBP | GT Biopharma Inc
| GTB-3650 For Treatment of CD33+ Leukemia | Phase 1 | 08/11/2025 7:10 AM | Dose Update | | |
STOK | Stoke Therapeutics Inc
| zorevunersen For the treatment of Dravet syndrome with a confirmed mutation, | Phase 3 | 08/11/2025 7:08 AM | Dosing Update | | |
AMPH | Amphastar Pharmaceuticals Inc
| Venofer In patients with chronic kidney disease (CKD). | — | 08/11/2025 6:03 AM | FDA approved | | |
NVSNVSEF | Novartis AG
| ianalumab In adults with active Sjögren's disease. | Phase 3 | 08/11/2025 3:47 AM | Top-line results | | |
NYXH | Nyxoah SA
| Genio For the Treatment of Obstructive Sleep Apnea | — | 08/08/2025 4:53 AM | FDA approved | | |
ARVN | Arvinas Inc
| Vepdegestrant For ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. | New Drug Application (NDA) | 08/08/2025 4:51 AM | FDA Accepted | | |
CAPR | Capricor Therapeutics Inc
| deramiocel For the treatment of Duchenne muscular dystrophy (DMD) | Type A Meeting | 08/08/2025 9:00 AM | FDA Meeting | | |
ASMB | Assembly Biosciences Inc
| ABI-5366 For recurrent genital herpes. | — | 08/08/2025 8:39 AM | Positive Results | | |
NTRB | Nutriband Inc
| AVERSA An abuse-deterrent fentanyl transdermal patch. | Type C Meeting | 08/08/2025 8:36 AM | FDA GRANT | | |
IXHL | Incannex Healthcare Limited
| IHL-42X Obstructive Sleep Apnoea (OSA) | Phase 2 | 08/08/2025 8:31 AM | Findings Update | | |
OBIO | Orchestra BioMed Holdings Inc
| BACKBEAT AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. | — | 08/08/2025 7:21 AM | FDA approved | | |
PALI | Palisade Bio, Inc.
| PALI-2108 For patients affected by UC. | — | 08/07/2025 9:34 AM | New Data | | |
VTVT | vTv Therapeutics Inc
| Cadisegliatin For Type 1 Diabetes | Phase 3 | 08/07/2025 8:38 AM | Provided Update | | |
SLS | SELLAS Life Sciences Group Inc
| galinpepimut-S (GPS) Targets the WT1 protein, which is present in an array of tumor types. | Phase 3 | 08/07/2025 8:35 AM | Analysis | | |
FGENALPMFALPMY | FibroGen Inc Astellas Pharma Inc
| roxadustat Anemia of chronic kidney disease (CKD) | Type C Meeting | 08/07/2025 7:59 AM | Positive Feedback | | |
| | CYB003 Major Depressive Disorder | — | 08/07/2025 7:57 AM | Application Approved | | |
LLY | Eli Lilly and Co
| orforglipron Orforglipron for the treatment of obesity and overweight | Phase 3 | 08/07/2025 6:24 AM | Top-line results | | |
| | OST-HER2 In patients with HER2-expressing solid tumors in breast cancer and other cancers | — | 08/07/2025 6:22 AM | Provided Update | | |
| | tegoprubart For Type 1 Diabetes | Phase 1b | 08/06/2025 5:43 PM | Updated data | | |
CMRXJAZZ | Chimerix Inc Jazz Pharmaceuticals PLC
| dordaviprone treatment for recurrent H3 K27M-mutant diffuse glioma | — | 08/06/2025 5:40 PM | FDA GRANT | | |
IMMX | Immix Biopharma, Inc.
| NXC-201 NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. | — | 08/06/2025 5:38 PM | Provided Update | | |
RNXT | RenovoRx, Inc.
| RenovoCath Solid Tumors | — | 08/06/2025 5:36 PM | Provided Update | | |
KROS | Keros Therapeutics Inc
| KER-065 To treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins | — | 08/06/2025 5:34 PM | Provided Update | | |
MAT | Mattel Inc
| Barbie type 1 diabetes (T1D) | — | 08/06/2025 5:29 PM | Provided Update | | |
CING | Cingulate Inc.
| CTx-1301 Attention Deficit/Hyperactivity Disorder (ADHD) | — | 08/06/2025 9:13 AM | NDA Filing | | |
ACTU | Actuate Therapeutics Inc
| elraglusib In relapsed/refractory Ewing Sarcoma (r/r EWS). | Phase 1b | 08/06/2025 9:12 AM | Trial Initiation | | |
MBRX | Moleculin Biotech Inc
| Annamycin Soft tissue sarcoma (STS) lung metastases | — | 08/06/2025 9:11 AM | Presentation | | |
ICU | SeaStar Medical Holding Corporation
| NEUTRALIZE-AKI In adults with acute kidney injury | — | 08/06/2025 9:09 AM | Enrollment Plan | | |
LTRN | Lantern Pharma Inc
| LP-184 Prostate cancer | Investigational New Drug (IND) | 08/06/2025 8:22 AM | FDA Clearance | | |
BTAI | BioXcel Therapeutics Inc
| BXCL501 (dexmedetomidine) For dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist | — | 08/06/2025 8:20 AM | Publication | | |
ADIL | Adial Pharmaceuticals Inc
| AD04 Alcohol Use Disorder (AUD) | Phase 2 | 08/06/2025 8:17 AM | FDA Meeting | | |
LNTH | Lantheus Holdings Inc
| Piflufolastat F 18 (formerly 8F-DCFPyL) Biochemically Recurrent Prostate Cancer (CONDOR) | New Drug Application (NDA) | 08/06/2025 8:05 AM | FDA Accepted | | |
TEVATEVJF | Teva Pharmaceutical Industries Ltd
| AJOVY (Fremanezumab-vfrm) Comorbid depression, anxiety or hypertension, as well as migraine | — | 08/06/2025 8:03 AM | FDA approved | | |
DTIL | Precision BioSciences Inc
| PBGENE-HBV For chronic hepatitis B virus (HBV) | — | 08/06/2025 7:59 AM | Results | | |
| | CardiolRx Acute Myocarditis | Phase 2 | 08/06/2025 7:53 AM | Top-line results | | |
GLPGGLPGF | Galapagos NV
| GLPG5101 In patients with relapsed/refractory chronic lymphocytic leukemia | Regenerative Medicine Advanced Therapy (RMAT) Designation | 08/06/2025 4:30 AM | Designation Grant | | |
URGN | UroGen Pharma Ltd
| ZUSDURI for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). | — | 08/05/2025 8:12 AM | Provided Update | | |
WINT | Windtree Therapeutics Inc
| Istaroxime Cardiogenic Shock in severe acute heart failure | — | 08/05/2025 9:05 AM | Data | | |
| | SENTI-202 Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia | Phase 2 | 08/05/2025 8:36 AM | Provided Update | | |
NUWE | Nuwellis Inc
| Aquadex SmartFlow® For patients suffering from hypervolemia (fluid overload). | — | 08/05/2025 8:25 AM | Provided Update | | |
| | CMND-100 For Treatment Of AUD | — | 08/05/2025 8:24 AM | Approved | | |
| | NPM-139 Subdermal GLP-1 implant in development for chronic weight management | Phase 1 | 08/05/2025 8:22 AM | Results | | |
NUVB | Nuvation Bio Inc.
| IBTROZI In Advanced ROS1-Positive Non-Small Cell Lung Cancer | — | 08/05/2025 8:20 AM | Data Presentation | | |
IMMPPRRUF | Immutep Ltd
| eftilagimod alpha For cancer and autoimmune disease | — | 08/05/2025 8:17 AM | Positive Feedback | | |
COCP | Cocrystal Pharma Inc
| CDI-988 For Pandemic Norovirus and Coronavirus | Phase 1 | 08/05/2025 8:06 AM | Presentation | | |
IVBIYIVBXF | Innovent Biologics Inc
| Taletrectinib ROS1-Positive Non-Small Cell Lung Cancer | — | 08/05/2025 8:06 AM | Data Presentation | | |
AMRX | Amneal Pharmaceuticals Inc
| CREXONT For Treatment of Parkinson's Disease | — | 08/05/2025 7:41 AM | Marketing authorization | | |
| | ELI-002 For patients with mutant Kirsten rat sarcoma | — | 08/05/2025 7:10 AM | Provided Update | | |
| | Tecarfarin For Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts | — | 08/05/2025 6:10 AM | Clinical Trial | | |
BMYBMYMP | Bristol-Myers Squibb Company
| Breyanzi (lisocabtagene maraleucel) Second-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL) | supplemental Biologics License Applications (sBLA) | 08/04/2025 4:54 PM | Application Accepted | | |
VRTX | Vertex Pharmaceuticals Inc
| VX-993 For the Treatment of Acute Pain | Phase 2 | 08/04/2025 4:46 PM | Top-line results | | |
AIM | AIM ImmunoTech Inc
| Ampligen COVID-19 and Other Respiratory Viral Diseases | — | 08/04/2025 9:22 AM | Provided Update | | |
CASI | CASI Pharmaceuticals Inc
| CID-103 Relapsed Or Refractory Multiple Myeloma | — | 08/04/2025 9:07 AM | FDA Clearance | | |
SONN | Sonnet BioTherapeutics Holdings Inc
| SON-1010 Advanced Solid Tumors | — | 08/04/2025 8:47 AM | Clinical Study | | |
| | Swoop® System Sequences Portable MR Imaging® System | — | 08/04/2025 8:12 AM | Enrollment Update | | |
| | TH104 For Chronic Pruritis in Primary Biliary Cholangitis (PBC) | — | 08/04/2025 8:11 AM | Provided Update | | |
INMB | INmune Bio Inc
| INKmune High-Risk Myelodysplastic Syndrome (MDS) | Phase 1/2 | 08/04/2025 8:10 AM | Provided Update | | |
AIMD | Ainos, Inc.
| VELDONA Potential Treatment of Oral Warts in HIV-Seropositive | Taiwan's Food and Drug Administration (TFDA) | 08/04/2025 8:08 AM | Approved | | |
TMDX | TransMedics Group Inc
| OCS™ Heart System For patients with end-stage lung, heart, and liver failure | Investigational Device Exemption | 08/04/2025 8:04 AM | Conditional approval | | |
LCTX | Lineage Cell Therapeutics Inc
| OPC1 Treatment of Chronic and Subacute Spinal Cord Injury | — | 08/04/2025 8:03 AM | Provided Update | | |
DYN | Dyne Therapeutics Inc
| DYNE-251 Duchenne Muscular Dystrophy | Breakthrough Therapy Designation | 08/04/2025 7:36 AM | Designation Grant | | |
DYN | Dyne Therapeutics Inc
| DYNE-251 Duchenne Muscular Dystrophy | Biologics License Applications (BLA) | 08/04/2025 7:37 AM | BLA Filing | | |
SAVA | Cassava Sciences Inc
| Simufilam Alzheimer's Disease | — | 08/04/2025 7:38 AM | Positive Results | | |
BCDA | BioCardia Inc
| CardiAMP Designed to be a comprehensive biotherapeutic heart failure solution | — | 08/04/2025 6:04 AM | Regulatory Update | | |
ALLO | Allogene Therapeutics Inc
| Cemacabtagene Ansegedleucel For Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse | — | 08/01/2025 4:19 PM | Provided Update | | |
XCUR | Exicure Inc
| burixafor In Multiple Myeloma | Phase 2 | 08/01/2025 4:14 PM | Provided Update | | |
BTAI | BioXcel Therapeutics Inc
| IGALMI™ Sublingual film | Phase 3 | 08/01/2025 7:04 AM | Pivotal Study | | |
VTRS | Viatris Inc
| meloxicam For the Treatment of Moderate-to-Severe Acute Pain | Phase 3 | 08/01/2025 4:07 PM | Abstract | | |
ARTL | Artelo Biosciences Inc
| ART12.11 For overcoming problematic drug properties which allows for precise control over purity, potency, and consistency. | — | 08/01/2025 7:48 AM | Provided Update | | |